astria therapeutics glp-1 receptor agonist weight management diabetes treatments Advances in agonists delivery systems for obesity and GLP-1 Receptor Agonist Services for

A pure glucagon agonist, HM15136 (Hanmi Pharmaceutical) is in phase 1 trials

GLP-1RAs exert glycemic control through multiple mechanisms, including the stimulation of insulin secretion under hyperglycemic conditions, suppression of glucagon secretion during hyperglycemia, deceleration of gastric emptying to mitigate postprandial glucose spikes, reduction of caloric intake, and promotion of weight loss.71,8183 Short-acting GLP-1RAs, such as exenatide and lixisenatide, primarily reduce nocturnal and fasting glucose levels, while maintaining their effect on gastric emptying over prolonged treatment periods

Table 1 below depicts some of the more prolific GLP-1 drugs approved by the FDA

They provide a comprehensive strategy for cardiovascular health by enhancing vascular function, lipid profiles, and blood pressure [99]

GLP-1- based treatments for T2DM, such as GLP-1 receptor agonists, dual and triple agonists that activate GLP-1R, GIPR, and glucagon receptors, and dipeptidyl peptidase-4 (DPP-4) inhibitors have been reviewed here

Preliminary research suggests it may influence incretin hormone pathways, though clinical evidence supporting meaningful GLP-1 or GIP enhancement in humans is lacking